Unesbulin

DRUG3 trials

Sponsors

University of Oklahoma, PTC Therapeutics

Conditions

LeiomyosarcomaOvarian Cancer

Phase 1

Unesbulin in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy

CompletedNCT03206645

University of OklahomaOvarian Cancer

Start: 2017-08-28End: 2024-03-31Updated: 2024-04-23

A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)

CompletedNCT03761095

PTC TherapeuticsLeiomyosarcoma

Start: 2019-03-13End: 2024-02-05Updated: 2024-03-15

Phase 2

A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

TerminatedNCT05269355

PTC TherapeuticsLeiomyosarcoma

Start: 2022-05-23End: 2024-07-17Updated: 2025-06-13

Related Papers

Phase IB trial of the BMI-1 inhibitor unesbulin plus neoadjuvant paclitaxel-carboplatin in advanced ovarian cancer

Journal of Ovarian Research2026-08-25

The Effect of Food on the Pharmacokinetics of Unesbulin in Patients with Advanced Leiomyosarcoma

Journal of Clinical Haematology2025-01-01

A phase 1b study of unesbulin (PTC596) plus dacarbazine for the treatment of patients with locally recurrent, unresectable, or metastatic relapsed/refractory leiomyosarcoma.

Journal of Clinical Oncology2022-06-019 citations